FORT WORTH, June 21, 2023 – Alcon, the global leader in eye care, will showcase cutting-edge innovations from advances in the reusable lens space to seamless digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and try-ons, Alcon will help Eye Care Professionals (ECPs) bring innovation to life in their practices. Alcon will connect ECPs with the TOTAL solution for monthly lens-wearing patients and offer an exclusive preview of Alcon’s pipeline innovations. Alcon’s digital ordering platform, MARLO, will also be on display through the interactive MARLO Experience Center.

“Alcon is proud to be in the vanguard of technological innovation for the eye care industry,” said Sean Clark, General Manager, U.S. Vision Care, Alcon. “Our calling to support and deliver solutions for Eye Care Professionals and their patients is what drives this unyielding pursuit of scientific advancement. We are thrilled to share the fruits of this dedication with attendees at Optometry’s Meeting this year.”

Alcon to Bridge the Comfort Divide for Reusable Patients with the TOTAL Solution - TOTAL30^®, TOTAL30^® for Astigmatism, and preview of upcoming portfolio additions

Alcon will host a series of sponsored events, where key opinion leaders will share TOTAL30 portfolio highlights, including how the innovations have been instrumental to their practices’ success. Experts will also delineate the science behind TOTAL30 and TOTAL30 for Astigmatism, the first and only reusable Water Gradient lens for toric lens patients.¹ Highlights will showcase the reusable, Water Gradient design of TOTAL30 for Astigmatism, including other features, such as biomimetic CELLIGENT™ Technology that helps resist bacteria and lipid deposits for a clean lens all month long^2-6 and the lens’ PRECISION BALANCE 8|4^® design that provides the on-eye stability astigmatic contact lens wearers need for exceptionally clear and stable vision.⁷ Throughout the sponsored events, Alcon’s experts will demonstrate practical solutions to achieving patient satisfaction as well as preview highly anticipated innovations set to launch early next year.

Alcon’s booth #1211 will serve as the exclusive source for information on the company’s current offerings and launch details for future innovations. Attendees can stop by Alcon’s booth for the TOTAL30 Try-On Event. Alcon representatives will be available at the booth for the Try-On Event and to provide more information on the next generation of TOTAL30 innovation.

Alcon will also be providing Ask the Experts sessions focusing on the company’s reusable contact lens portfolio, including TOTAL30 and TOTAL30 for Astigmatism. Experts will share key facts about the innovations, in addition to insights about the reusable lens-wearing experience. These interactive sessions will offer attendees the opportunity to learn more about Alcon’s TOTAL30 offerings.

MARLO Innovations Bring Seamless Digital Connectivity to ECPs and Patients

Attendees will also be able to visit the MARLO Experience Center for an Ask the Experts session and live demonstrations at Alcon’s booth. The company will highlight how MARLO is revolutionizing the eye care industry by delivering a cutting-edge digital platform for eye care practices with a patient-centric user experience in mind.

Visit Alcon booth #1211 for the TOTAL30 Try-On Event, MARLO live demonstrations, and details on upcoming innovation launches.

For more information on the products and programs featured in this press release, and details on Alcon’s booth activities, including dates and times, visit www.myalcon.com/professional/events/aoa2023.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

As the global leader in eye care with a heritage spanning over 75 years, Alcon offers the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Trademarks are the property of their respective owners.

References

1. A02491-REP-198231-1 Outermost Surface Softness Analysis of lehfilcon A Contact Lenses and Correlation with Water Content Based upon Petrisoft Gels.
2. Montaquila S, Gustafson B, Whaley S, Subramanian V. Clinical performance evaluation of lehfilcon A monthly replacement, silicone hydrogel toric contact lenses. Optom Vis Sci. 2021;98:E-abstract 215050.
3. Ishihara K, Fukazawa K, Sharma V, Liang S, et al. Antifouling silicone hydrogel contact lenses with a bioinspired 2-methacryloyloxyethyl phosphorylcholine polymer surface. ACS Omega. 2021;6:7058-7067.
4. Harris V, Pifer R, Shannon P, Crary M. Low in vitro Pseudomonas aerunginosa adhesion to lehfilcon A contact lenses. Invest Ophthalmol Vis Sci. 2022;63:541.
5. Pifer R, Harris V, Crary M, Shannon P. Low in vitro Serratia marcescens adhesion to lehfilcon A contact lenses. Invest Ophthalmol Vis Sci. 2022;63:541.
6. In vitro evaluation of lipid deposition for lehfilcon A and commercial lenses using 3D confocal imaging; Alcon data on file, 2021.
7. In a clinical study wherein patients (n=66) used AOSEPT^® solution for nightly cleaning, disinfecting, and storing; Alcon data on file, 2021.

See product instruction for complete wear, care, and safety information. May not be available in all markets.

Connect with us on Facebook and LinkedIn.

Media Relations

Steven Smith
+ 1 817 551 8057 (Fort Worth)
[email protected]

Investor Relations

Allen Trang
+ 1 817 615 2789 (Fort Worth)
[email protected]